XTalks Follow Up

Reimagining Clinical Trial Interoperability: From Fragmented Data to Faster Decisions

The life sciences industry does not have a technology problem. It has connectivity and decision velocity problem.

Over the past decade, organizations have invested billions in digital platforms, cloud infrastructure, and advanced analytics. Yet clinical teams still struggle to access trusted information when and where decisions need to be made.

The result is a paradox: life sciences has more data than ever before, but often lacks the connected intelligence required to accelerate development, reduce risk, and bring therapies to patients faster.

Yet one problem continues to slow innovation: clinical trial interoperability.

During a recent Xtalks webinar, Infiligence CEO Ram joined industry leaders to discuss a critical question facing the industry: how can life sciences organizations move beyond disconnected systems toward truly connected clinical ecosystems?

Here are the key takeaways from the webinar. You can also access the full webinar here.

Interoperability Is No Longer an Engineering Challenge. It Is a Business Model Challenge.

More Technology Hasn't Meant Better Connectivity

Today's clinical trials typically rely on 15–20 different applications to manage study execution. Clinical data, Trial Master Files (TMF), EDC systems, safety platforms, imaging, laboratory systems, biomarker data, and analytics platforms all operate independently.

Every new system promises efficiency. Collectively, they often create more complexity.

The result is an ecosystem where teams spend valuable time reconciling data instead of generating insights.

For organizations pursuing digital transformation, this creates an important question.

Why are we still integrating systems instead of integrating decisions?

The Hidden Cost of Fragmentation

Most organizations measure fragmentation through integration costs and operational inefficiencies. However, the greatest impact is less visible: delayed decisions.

• Delayed enrollment decisions
• Delayed safety signals
• Delayed forecasting
• Delayed regulatory readiness

Clinical operations teams often wait days or even weeks before they trust the data enough to make decisions. During that delay, protocol deviations continue, enrollment slows, manufacturing plans shift, and commercialization timelines become harder to predict.

As a result, disconnected data slows every decision across the development lifecycle.

Standards Alone Won't Solve Clinical Trial Interoperability

The industry has invested heavily in standards like CDISC, ODM, and more recently USDM.

These standards provide an important foundation.

But standards only create value when organizations consistently adopt them.

Today, implementation varies widely across sponsors, CROs, technology vendors, and service providers. Even when organizations use the same standards, they often interpret them differently.

Interoperability requires a shared understanding of what data means, which doesn’t come from organizing data in same file format alone.

Why AI Changes the Conversation?

This is where AI in clinical trials becomes transformative.

AI changes interoperability from a manual engineering exercise into an intelligent orchestration challenge.

AI can dramatically reduce integration effort by:

• Mapping data between systems automatically
• Understanding relationships between different clinical concepts
• Creating a common semantic layer across structured and unstructured data
• Accelerating validation of mappings while keeping humans involved for complex scenarios

Integrations that previously required weeks of manual work can increasingly be completed in hours. More importantly, AI shifts interoperability away from rigid point-to-point integrations toward shared understanding. Natural language becomes the bridge between systems.

The Future of Life Sciences Data Integration

The webinar highlighted an interesting comparison with financial services. Banking solved many interoperability challenges through four key principles:

• Shared definitions
• Trusted connectivity
• Regulatory incentives
• Complexity hidden behind simple interfaces

Life sciences now face a similar opportunity: creating trusted connectivity that allows innovation to scale without increasing complexity.

Organizations should not build hundreds of custom integrations every time they launch a study. Instead, the industry needs a neutral interoperability layer that enables systems to exchange trusted information through standardized semantics and open APIs.

Emerging technologies like Model Context Protocol (MCP), machine-readable protocols, and AI-native integration architectures are bringing this vision much closer.

Why Open Ecosystems Will Win?

Another trend discussed during the session is already reshaping software purchasing. Pharmaceutical companies increasingly want ownership of their digital experiences. Rather than working entirely within vendor interfaces, they want direct access to APIs and data so they can build workflows tailored to their organizations.

This represents a major shift.

Technology vendors that continue to rely on closed ecosystems risk becoming infrastructure providers rather than strategic partners. Open architectures will increasingly become a competitive advantage.

The Industry Needs Better Incentives

One of the most important observations from the discussion was that interoperability has become an economic challenge rather than an engineering challenge. Many organizations still benefit financially from manual reconciliation, disconnected systems, and proprietary workflows. Without better incentives, even the best technologies struggle to gain widespread adoption.

• Progress requires collaboration across the ecosystem.
• Regulators can encourage interoperable approaches through guidance and initiatives rather than mandates.
• Technology vendors must embrace open APIs and shared standards.
• Sponsors should prioritize platforms that make data portable rather than proprietary.

The Infiligence Perspective

At Infiligence, we believe the future of life sciences data integration is not another platform. It is an intelligent interoperability layer that allows existing investments to become more valuable.

It is an intelligent layer that connects existing platforms.

Organizations don't need to replace every clinical application they already own.

They need AI-native capabilities that understand data across systems, automate integration, govern AI safely, and deliver trusted insights when decisions matter most.

This is why we focus on combining AI-native engineering, governed data platforms, validation expertise, and AI governance into a single operating model.

Interoperability should no longer be measured by the number of APIs connected.

It should be measured by how quickly organizations can move from fragmented data to confident decisions.

Looking Ahead

Clinical trial interoperability will define the next generation of digital transformation in life sciences.

The organizations that succeed will not necessarily have the most technology.

They will have the most connected technology.

Interoperability is no longer about moving data between systems.

It is about enabling faster, smarter, and more confident decisions across the entire life sciences ecosystem.

That is the connected enterprise Infiligence is helping build.